Trial reportDigestive diseases and sciences2016
Short-Term Effects of Relamorelin on Descending Colon Motility in Chronic Constipation: A Randomized, Controlled Trial.
Trial report in Digestive diseases and sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 30 citations in OpenAlex.
- Effects of ghrelin receptor agonist, relamorelin, on gastric motor functions and satiation in healthy volunteers.Neurogastroenterology and motility · 2016Trial
- Sites and mechanisms of action of colokinetics at dopamine, ghrelin and serotonin receptors in the rodent lumbosacral defecation centre.The Journal of physiology · 2023Article
- Chronic Idiopathic Constipation in Adults: A Review on Current Guidelines and Emerging Treatment Options.Clinical and experimental gastroenterology · 2021Review
- Neuroimmunophysiology of the gut: advances and emerging concepts focusing on the epithelium.Nature reviews. Gastroenterology & hepatology · 2018Review
- New treatments and therapeutic targets for IBS and other functional bowel disorders.Nature reviews. Gastroenterology & hepatology · 2018Review
- Neural pathways for colorectal control, relevance to spinal cord injury and treatment: a narrative review.Spinal cord · 2018Review
- Prokinetics in the Management of Functional Gastrointestinal Disorders.Current gastroenterology reports · 2017Review
- Intractable Constipation in the Elderly.Current treatment options in gastroenterology · 2017Review
- Evidence that central pathways that mediate defecation utilize ghrelin receptors but do not require endogenous ghrelin.Physiological reports · 2017Article
- Small Bowel Motility.Current gastroenterology reports · 2017Review
- Future Treatment of Constipation-associated Disorders: Role of Relamorelin and Other Ghrelin Receptor Agonists.Journal of neurogastroenterology and motility · 2017Review
- Measurement of Gastrointestinal and Colonic Motor Functions in Humans and Animals.Cellular and molecular gastroenterology and hepatology · 2016Article
- Relamorelin to Treat Constipation: "Pusher" or Pushover?Digestive diseases and sciences · 2016Article
- Disorders of gastrointestinal hypomotility.F1000Research · 2016Review
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe pentapeptide ghrelin agonist, relamorelin, accelerates colonic transit in patients with chronic constipation (CC). In a murine model, relamorelin decreased excitability of colonic circular smooth muscle cells and colonic intraluminal pressure.
aimTo determine short-term effects of relamorelin on colonic motility measured by barostat and multilumen manometry in CC.
methodsIn a placebo-controlled, single-dose, double-blind, randomized study in patients with CC, we investigated the motor effects of relamorelin, 100 μg, SQ (12 patients) compared to placebo SQ (six patients). A motility-barostat balloon assembly was used to measure colonic compliance; tone and phasic pressure activity were measured before and after a 1000-kcal milkshake meal (administered ~60 min post-medication). Overall "background" phasic pressure activity was assessed by: average amplitude and motility index (MI = ln[sum amplitudes × #contractions + 1]) over defined periods. High-amplitude propagating contractions (HAPCs) were characterized by amplitude >75 mmHg and propagating contractions >50 mmHg; both were propagated over at least 10 cm. Postprandial HAPCs were the primary end point. The study sample had 80% power to detect an increase of 3.3 HAPCs in the hour post-meal.
resultsRelamorelin, 100 μg, significantly induced more pre-meal propagated contractions [PCs of either >50 or >75 mmHg] compared to placebo (p < 0.05). Relamorelin also induced more post-meal PCs >50 or >75 mmHg than placebo. Relamorelin did not significantly alter colonic compliance, fasting or postprandial phasic pressure activity (20 min pre-meal fasting MI) or tone, and 60 min postprandial phasic pressure amplitude or MI, or tone.
conclusionsRelamorelin stimulates propagated colonic contractions without alteration of background irregular contractions in CC. ClinicalTrial.Gov registration number: NCT 01781104.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.